Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell surface markers

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44300   clinical trials with a EudraCT protocol, of which   7354   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    66 result(s) found for: Cell surface markers. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2022-001585-36 Sponsor Protocol Number: AMC_SMILE_1.0 Start Date*: 2022-07-05
    Sponsor Name:Amsterdam UMC
    Full Title: EffectS of L-glutaMIne on oxIdative stress, sickLE erythrocyte viability, inflammation and endothelial activity in sickle cell disease (SMILE trial)
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000581-10 Sponsor Protocol Number: 12OY006 Start Date*: 2013-07-25
    Sponsor Name:Nottingham University NHS Trust
    Full Title: Evaluation of inflammatory markers in patients on topical anti-glaucoma drop therapy; a comparative trial of preserved and non-preserved primary medical treatment (eye drops) in patients with glauc...
    Medical condition: Glaucoma is the condition that is being treated by these eye drops - however the study is aimed at measuring the amount of inflammation that develops on the surface of the eye when these drops are ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000411-91 Sponsor Protocol Number: NKZellen-Version1.0 Start Date*: 2013-02-13
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial
    Medical condition: relapsing-remitting multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017525-19 Sponsor Protocol Number: 77777 Start Date*: 2010-03-12
    Sponsor Name:St. Vincents University Hospital, Department of Rheumatology.
    Full Title: Abatacept in Psoriasis and Psoriatic Arthritis: a single centre, placebo-controlled, crossover study in 15 patients.
    Medical condition: Psoriatic Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002733-10 Sponsor Protocol Number: Dual-Triple-ART Start Date*: 2019-08-13
    Sponsor Name:FUNDACIÓ LLUITA CONTRA LA SIDA
    Full Title: Exploratory, open-label, randomized clinical trial to assess the efficacy of first-line dual vs. triple antiretroviral therapy (art) in hiv-1 reservoir and in peripheral compartments in hiv-infecte...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10008919 Chronic HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-001775-20 Sponsor Protocol Number: CHDR1644 Start Date*: 2018-07-12
    Sponsor Name:Centre for Human Drug Research
    Full Title: Immunomonitoring of tacrolimus in healthy volunteers
    Medical condition: Immunesuppression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004995-17 Sponsor Protocol Number: NL7507301820 Start Date*: 2021-03-11
    Sponsor Name:AMsterdam UMC-AMC
    Full Title: Low dose iron chelation as TReatment of Oxidative stress in Sickle cell disease; TROS study
    Medical condition: Sickle cell disease (an hereditary hemoglobinopathy)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003217-33 Sponsor Protocol Number: ViDImmun Start Date*: 2013-02-04
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Immunological response of a single dose of 100,000 I.U. of cholecalciferol (vitamin D3)
    Medical condition: relative vitamin D3 deficiency
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004861 10046242 Unspecified vitamin D deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002894-36 Sponsor Protocol Number: IXIARO-booster-senescence Start Date*: 2017-12-22
    Sponsor Name:Medical University of Vienna (MUW)
    Full Title: "An open, monocentric, uncontrolled phase 4 trial to characterise cellular and humoral immune responses following the first booster immunisation with the inactivated, purified Japanese Encephalitis...
    Medical condition: The condition under investigation is the naturally aging immune system. The aim of this study is to investigate the immune responses following a booster immunisation with the Japanese Encephalitis ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001971-61 Sponsor Protocol Number: SALYCENDO Start Date*: 2016-08-29
    Sponsor Name:Radboudumc
    Full Title: The effects of acetylsalicylic acid on immunoparalysis following human endotoxemia.
    Medical condition: We will investigate the effects of acetylsalicylic acid on immunoparalysis following human endotoxemia in healthy male volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005024-10 Sponsor Protocol Number: I6F-MC-JJCB Start Date*: 2015-07-29
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients
    Medical condition: T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002735-23 Sponsor Protocol Number: IPROTECT1 Start Date*: 2013-12-04
    Sponsor Name:InnaVirVax SA
    Full Title: Assessment of the therapeutic properties of the VAC-3S immunoprotective vaccine when combined with standard antiretroviral therapy (ART) in the course of HIV-1 infection. A European multicenter, r...
    Medical condition: Chronically infected HIV-1 patients under viral control on Anti-Retroviral therapy
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005791-32 Sponsor Protocol Number: HF0220/003 Start Date*: 2006-04-24
    Sponsor Name:Hunter-Fleming Ltd
    Full Title: Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease.
    Medical condition: HF0220 experimentally appears to exert its potential beneficial effects within the CNS and possibly other tissues by attenuating the adverse effects of oxidative stress. It is believed that this me...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000308-12 Sponsor Protocol Number: P150941J Start Date*: 2020-11-06
    Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Full Title: « Mesenchymal stromal cells treatment in Lyell syndrome: A pilot phase 1-2 open trial”
    Medical condition: Patients: Adults diagnosed with SJS-TEN with at least 10% of body surface area involved.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10025166 Lyell syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002528-34 Sponsor Protocol Number: HO158 Start Date*: 2020-10-01
    Sponsor Name:HOVON Foundation
    Full Title: First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in complete remission and/or with detectable bone marrow mi...
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022681-27 Sponsor Protocol Number: O-DEX-1 Start Date*: 2010-11-09
    Sponsor Name:University Hospital Brno
    Full Title: Ofatumumab Added to Dexamethasone in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia
    Medical condition: Patients with refractory/relapsed CLL
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000201-72 Sponsor Protocol Number: 1 Start Date*: 2012-05-11
    Sponsor Name:University of Aberdeen [...]
    1. University of Aberdeen
    2. University of Aberdeen
    Full Title: The Effects of Inorganic Nitrite on cardiac and skeletal muscle: Physiology, Pharmacology and Therapeutic Potential. Peripheral Arterial Disease
    Medical condition: Peripheral arterial Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004313-15 Sponsor Protocol Number: NI-0401-01 Start Date*: 2006-07-14
    Sponsor Name:NovImmune S.A.
    Full Title: A Phase I/IIa, Double-blind, Randomized, Placebo-controlled, Dose-Escalation Study of NI-0401 in Patients with Moderate to Severe Active Crohn´s Disease
    Medical condition: Moderate to Severe Active Crohn´s Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011538-93 Sponsor Protocol Number: Maraviroc –switch Start Date*: 2010-06-07
    Sponsor Name:Imperial College London
    Full Title: A prospective, randomised study to access safety, changes in platelet reactivity, plasma cardiac biomarkers and metabolic parameters over 48 weeks in HIV-1 infected subjects undergoing a switch in...
    Medical condition: HIV
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004501-24 Sponsor Protocol Number: CT-2011-01 Start Date*: 2012-03-06
    Sponsor Name:CureTech Ltd.
    Full Title: Phase II study to evaluate the safety, tolerability and efficacy of CT-011 administered intravenously to patients with metastatic melanoma
    Medical condition: Metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA